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ABSTRACT 
Tumor suppressor p53 (Tp53) is mutated in around half of human cancers, while in wild type 
p53 cells its activity is continuously inhibited by MDM2 through proteasome degradation 
resulting in the loss of its function. Currently, cancer treatments with small molecules based on 
reactivation of wild type p53 and restoration of mutant p53 have moved to clinical trials and 
exhibited promising anti-cancer effects. Our lab previously found a small molecule RITA 
which reactivates p53 and has strong anti-cancer effect without affecting normal cells. 
However, small molecules always have multiple targets and those should be validated for either 
predicting potential side effects or evaluating their efficacy in different types of cancers.  
In this thesis, we addressed a p53-independent mechanism of RITA along with two other anti-
cancer compounds Aminoflavone and Oncrasin-1. Using thermal proteome profiling (TPP) 
approach, we found that transcription machinery is commonly inhibited by these three 
compounds in a reactive oxidative species (ROS)-dependent manner. Global transcription 
inhibition results in massive downregulation of the majority of oncogenes as well as genes that 
are involved in homologous recombination (HR). By taking advantage of that, we performed 
combination treatments of these three compounds with PARP-1 inhibitors Olaparib and 
talazoparib. The combination treatments displayed clear synergistic anti-cancer effects in 
several cancer lines as well as in primary ovarian and breast cancer patient samples.    
Moreover, we found that mRNA translation is also inhibited by RITA through activation of 
eIF2α phosphorylation, in a p53-independent manner. Complementary to these findings, we  
discovered a potent downregulation of MDM2 by RITA. Using different approaches, we 
confirmed that MDM2 is not inhibited by RITA through proteasome degradation, autophagy 
or microRNAs-mediated translation inhibition. In addition, the inhibition of MDM2 is not the 
cause of cell death since both MDM2 overexpression and MDM2 KO could not rescue RITA 
killing effect. We conclude that, RITA dramatically inhibits RNA processing in cancer cells, 
leading to inhibition of transcription and translation, resulting in cell death.   
Reactivation of p53 also has dark sides which are related to p53-mediated growth arrest or 
apoptosis in normal tissues. We investigated the mechanism of action of the well-known p53 
inhibitor PFT-α and found that PFT-α cannot prevent p53 activation-induced growth repression 
in several cancer cell lines but can attenuate post-translational modifications (PTMs) of p53 
and by that differentially inhibit p53 target genes. Although we found that PFT-α exhibits 
strong intracellular antioxidant activity through activation of AHR/NRF2 pathway, we cannot 
link the antioxidant activity to its capacity to attenuate PTMs of p53. Worth to note, both PFT-
α and NAC can promote primary fibroblasts growth per se. Therefore, PFT-α rescued Nutlin-
3-induced growth repression in primary fibroblasts. Our findings suggest that caution needs to 
be taken when using PFT-α to study p53 signaling cascade, since it is not a pan-p53 inhibitor 
as it is described. The phenomenon we observed with PFT-α in primary fibroblasts also 
indicates the clinical potential of combining p53 reactivators with PFT-α in cancer therapies.  
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1 P53 AND CANCER 
 HISTORY OF P53 
In 1979, tumor suppressor p53 was discovered in mammalian cells which have been 
transformed by the SV40 DNA tumor virus 1–3. A co-transfection of p53 cDNA and ras 
oncogene into rat embryo fibroblasts leads to cell transformation, which suggested that p53 
gene was oncogene in the first place, much like the myc oncogene 4. Later, it was found that 
the p53 cDNA used for transfection was extracted from tumor cells bearing mutant p53, while 
wild type p53 cDNA from normal cells turned out to suppress tumor growth 5. Ever since, 
the importance of p53 as tumor suppressor is appreciated and p53 became the most studied 
cancer gene in the last four decades.  
As a transcription factor (for p53 protein structure, see Figure 1), p53 is the central 
determinant of cell fate: it induces cell cycle arrest by transactivating cyclin dependent kinase 
inhibitor p21 that inhibits phosphorylation of Rb and prevents cells from entering into S phase. 
It induces apoptosis by activating BH3 domain family members such as BBC3 (PUMA) and 
PMAIP1 (NOXA) which prevent anti-apoptotic members of BCL2 family from binding to 
pro-apoptotic proteins Bax and Bak. Bax and Bak form channels on the outer membrane of 
mitochondria to release cytochrome C, this triggers caspase 9-mediated apoptosis (reviewed 
in 6). Here, I will discuss the relationship between p53 and cancer hallmarks; MDM2/p53 
regulation; current compounds that reactivate or inhibit p53 and their clinical potential and 
identification of drug targets by using novel approaches. 
 
Figure 1. Human p53 protein: N-terminal transactivation domains TA1(1-40) and TA2 (40-60) are associated 
with transcription co-factors such as p300, CBP etc. TA1 also contains MDM2 binding site; Proline rich domain 
(64-95) binds to SH3 domain-proteins; DNA binding domain (102-292) is responsible for sequence-specific 
binding to p53’s response element on the promoter of its target genes; Nuclear localization signal (316-324); 
Tetramerization domain (325-355); C-terminal regulatory domain (364-393). 
 P53 REGULATION 
The activity of wild type p53 is regulated by many factors, for example, the expression of 
MDM2 directly affects p53 protein level 7; p53 transcription level is regulated and can be 
also modulated by epigenetic factors in a complex manner; chromatin remodeling enzymes 
such as HATs, HDACs, DNMT1 could also affect p53 gene expression 8–10.  Early in 1997, 
it was found in Mass’s lab by using a reporter plasmid vector that cytosine methylation of CpG 
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island in p53 promotor inactivates p53 gene expression. Abundant clinical results showed that 
aberrant promoter methylation of p53 is associated with carcinogenesis in different cancers 
including gliomas, epithelial ovarian cancer, breast cancer, adrenal cancer, head and neck 
cancer and leukemia (reviewed in 8). p53 gene expression is also protected by the insulator 
CTCF from repressive histone marks, such as H3K9me3, H3K27me3 and H4K20me3 10. 
PTMs can regulate p53 activity by affecting its stability or by recruiting other transcription 
co-factors (activators or repressors) to the promotor of its target genes 11. It is hypothesized 
that the profile of p53 PTMs induced by a specific stimulus forms a “barcode” which results in 
a specific cellular response 12. For example, phosphorylation of p53 on Ser46 was found to 
induce apoptosis but not cell-cycle arrest 13. p53’s stability, the affinity to its target genes and 
ability to recruit its partners can all be modulated in a complex and stimulus-dependent 
manner by diverse PTMs such as ubiquitination, phosphorylation, SUMOylation and 
acetylation, methylation as well. Since different PTMs could coexist on p53 and lead to 
diverse conformational changes of p53, it remains a challenge to characterize the correlation 
between specific PTMs and differential p53 tasks. In general, acetylation could activate p53 
which is supported by observation of enhanced p53 transcriptional activity and anti-cancer 
effects with HDAC inhibitor treatment. p53 function could be either activated or repressed by 
different states of methylation at different lysine sites of p53. Noteworthy, chromatin 
remodeling enzymes not only affect p53 expression but also modulate p53 activity by 
modulating PTMs of p53. For example, histone lysine methyltransferase KMT5 (Set9) mono-
methylate p53 at K372 and stabilizes p53, but KMT3C (Smyd2) and KMT5A (Set8) mono-
methylate p53 at K370 and K382, respectively , leading to prevention of p53-mediated 
CDKN1A (p21) and BBC3 (PUMA) induction (reviewed in 14). miRNA-125b, miRNA-
504, miRNA-25 and miRNA-30d can inactivate p53 pathway by directly binding to the UTR 
of p53 mRNA, while some miRNAs can regulate other factors such as MDM2, AKT and 
SIRT1 to indirectly affect p53 signaling pathway (reviewed in 15 ).  
In response to a number of cellular stresses including DNA damage, oncogene activation, 
hypoxia, nucleotide starvation, UV radiation etc., p53 can be activated physiologically and 
execute its transcription factor function (Figure 2). For example: oncogene-activated 
p19ARF sequesters MDM2 in the cytoplasm, where MDM2 undergoes proteasome 
degradation; the activated kinases such as ATM, ATR and Chk1/2 can phosphorylate p53 at 
its transactivation domains (TADs) and disrupt MDM2/p53 complex (reviewed in 16); it is 
also found that ATM can phosphorylate MDM2 at its RING domain, therefore inhibiting its 
E3 ligase activity (reviewed in 17); ATR is found to phosphorylate serine 407 of MDM2 and 
reduces p53 export from nucleus to cytoplasm 18.  
Upon pharmacological p53 reactivators such as Nutlin-3 and RITA, p53 can be stabilized by 
direct prevention of MDM2 binding (Figure 2), while conventional chemotherapeutic drugs 
such CPT, doxorubicin, cisplatin could stabilize p53 as a secondary event by activating ATM, 
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ATR, Chk1/2. There are many chemotherapeutic drugs used in clinic or in clinical trials that 
are known to activate p53 as well.  
Aminoflavone (AFP464, NSC 710464) is an anti-tumor compound which has already entered 
phase II clinical trials to treat estrogen-positive breast cancer (ER+) patients. AF is described 
to cause DNA damage after it is metabolized by CYP1A1, which is transcriptionally activated 
by AHR 19. In addition, AF also activates p53 and inhibits HIF1-α 20. Recently it has been 
shown that AF can modulate immune response by inducing anti-tumor M1 macrophage 
profile 21. Oncrasin-1(NSC743380) was identified to kill cancer cells with K-Ras mutation, 
but can also activate p53 22. Since p53 can be activated by many compounds as a secondary 
event, it is important to understand the primary mechanisms of action of these compounds 
for more efficient drug development (it is discussed further in chapter 3.2). 
 
 
Figure 2. p53 physiological activation: stress signals including hypoxia, UV irradiation, DNA damage, 
oncogene activation and nucleotide starvation  activate ATM, ATR and Chk1/2 which phosphorylate MDM2 
and p53, or induce p19ARF which inhibit MDM2, resulting in p53 stabilization and activation. p53 
pharmacological reactivation: Nutlin and RITA as examples of compounds reactivating p53 via inhibiting 
MDM2 binding to p53.    
 P53 AND MDM2 CIRCUIT 
p53 is well known as a sequence specific transcription factor. It consists of N-terminal region 
(residues 1-101) which contains two transactivation domains, TAD1 and TAD2, a proline-
rich region (PR), and nuclear export signal (NES) region; central core domain (amino acids 
102-292) which contains DNA-binding domain (DBD); C-terminal region (residues 292-393) 
which contains tetramerization domain (Tet, residues 325-355) 23, as shown in Figure 1. 
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Under unstressed conditions, wild type p53 level usually remains low due to MDM2-
mediated proteasome-dependent degradation 24. MDM2 is thoroughly characterized as a 
negative regulator of p53 (reviewed in 15). There are 4 well characterized domains of MDM2. 
At the N-terminus, residues 18-101 comprise the p53-binding region. This interaction inhibits 
the transcriptional activity of p53 by affecting the recruitment of canonical transcription 
factors (reviewed in 15). In addition, it is reported that MDM2 N-terminus interacts with p53 
C-terminus and could prevent proper p53 tetramerization 25. In the central region there is the 
central acidic domain (amino acids 237-288) adjacent to a zinc finger (residues 289-331). 
This part of the protein is described to interact with p53 central core domain and is essential 
for the ubiquitination of p53. The interaction could also lead to conformational changes of 
p53 and therefore affects p53 DNA binding activity 26. The C-terminus contains a RING 
finger (residues 436-482) that displays E3 ubiquitin ligase activity. It targets p53 to 
degradation but also regulates its own degradation. Loss of C-terminus RING finger results 
in both p53 and MDM2 stabilization 27. Its C-terminal tail region (residues 485-491) regulates 
RING finger motif by forming either MDM2 homodimer or MDM2-MDMX heterodimer 28.      
MDM2 is critical for maintaining p53 levels both in unstressed cells and following genotoxic 
stresses. In brief, once MDM2 binds to p53, it inhibits p53 transcriptional activity by binding 
to the TAD and DBD of p53,  then p53 is translocated by MDM2 from nucleus to cytoplasm, 
where p53 will be degraded by the 26S proteasome after undergoing MDM2-mediated 
ubiquitination  (reviewed in 16). Importantly, MDM2 contains p53-responisve promoter P2 
and is transactivated by cellular stress in a p53-dependent manner. This forms the 
components of p53-MDM2 negative feedback loop. Normally, this p53-MDM2 regulatory 
circuit can keep the level of wild type p53 in check to maintain cellular processes (reviewed 
in 15). However, overexpression of MDM2 is observed in many types of human cancers which 
exhibit loss of wild-type p53 characteristics (reviewed in 15).  
 MUTANT P53 IN CANCER 
As the guardian of genome, p53 is the most frequently mutated gene in human cancers, 
among which over 80% of the mutations are missense mutations that lead to the loss of DNA 
binding and wild type functions of p53 and exert dominant-negative effect over wild type 
p53 29. Around 30% of missense mutations are localized at so called 6 hot-spot residues in 
the DNA binding domain of p53 (R175, G245, R248, R249, R273, and R282) which are 
highly conserved during cancer evolution. Moreover, it has been discovered that mutant p53 
has gain-of-function that is independent of wild type p53 30. In addition to dominant-negative 
effects of mutant p53 which abrogate wild type p53 function, the mutant p53 gain-of function 
contributes to tumorigenesis, metastasis and resistance to cancer therapy 31. Mice bearing p53 
R270H or R172H developed tumors that are highly metastasized 32. It can be related to the 
fact that mutant p53 has been shown to support TGF-β-mediated metastasis 33. In the 
Vogelstein’s model of colon cancer, p53 mutation appears to be a late event, after APC 
mutation and beta-catenin accumulation 34 . Other researchers believe that p53 mutations can 
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occur at different stages of tumorigenesis and contribute to various cellular processes 
including enhanced cell growth, evasion of apoptosis, migration and invasion (reviewed in 
35).  
Selection pressure is considered to take place during the evolution of cancers. Some cancer 
cells manage to escape tumor suppression caused by wild type p53 and exhibit p53 null or 
p53 mutants eventually 36. It has been shown that mutant p53 can also activate the 
transcription of genes which are different from wild type p53 target genes, regardless of 
attenuation of DNA binding affinity 37. However, the mechanism is still not fully understood. 
It is known that wild type p53 needs to form a tetramer to properly function as a transcription 
factor. Theoretically, mutant p53 may alter the conformation of tetramer thereby being 
recruited by different co-factors to the promoters of different genes. p53 protein conformation 
is in a dynamic folded and unfolded status, which is considered being regulated by heat shock 
proteins such as Hsp70 or Hsp90. It is demonstrated that while Hsp70/Hdj1 system can shift 
wild type p53 to mutant-like conformation and enhance the unfolded state of mutant p53, 
Hsp90 counteracts Hsp70 to attenuate this conversion 38. 
Mutant p53-associated genetic abnormality is often correlated with poor prognosis in cancer 
patients 39. Li-Fraumeni patients carrying germline p53 mutations develop a wide spectrum 
of cancer types instead of specific tumor types 40,41. Therefore, it appears urgent to target 
mutant p53 as a therapeutic strategy to combat cancer. It is discussed more in chapter 3.2. 
2 P53 AND CANCER HALLMARKS 
Figure 3 illustrates how p53 is involved in cancer hallmarks, which is discussed in detail 
below. 
 PROLIFERATIVE SIGNALING   
Distinct from normal cells, cancer cells acquire the capability to sustain proliferative 
signaling through different mechanisms including autocrine signal stimulation, growth 
receptor overexpression or by educating neighbor cells to secret mitogens that promote tumor 
growth 42. In addition, cancer cells are able to maintain their proliferative state through 
ligand-independent pathways. For example, cancer cells can express structure altered growth 
receptors that can be active without binding to mitogens 43; cancer cells with Ras mutation 
maintain activated downstream pathways radiated from a ligand-stimulated receptor 
(reviewed in 44). It has been shown that loss of p53 is correlated with amplified growth 
signaling such as EGFR signaling 45,46, PDGFR-β signaling 47,48, hedgehog-GLI signaling 49–
51, NOTCH signaling 52–54 and NF-ĸB signaling 55. Both Ras and Myc oncogenes can activate 
p53 expression through ARF induction 56,57, in turn, p53 inhibits Ras and Myc to repress 
cancer cell growth, which serves as a barrier for tumor development 58,59. Therefore, the 
selection pressure for p53 mutations is very high. Consistently, it is well documented that 
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high expression of p53 mutants correlates with active growth receptor signaling in patients 
with different types of cancers 60–63. 
 GROWTH REPRESSION    
pRb and p53 are two major tumor suppressors that could call a halt to cell proliferation. 
Control of R-point transition of pRb function is perturbed in most of human tumors 59 (see 
Table 1). It is well known that p53 can prevent tumor cells from escaping growth arrest by 
inducing cyclin-dependent kinase inhibitor such as P21/WAF1/CIP1, which inhibits hyper-
phosphorylation of RB, therefore prevents E2F family members (mainly E2F1, E2F2 and 
E2F3) from transcribing genes that are needed for cells to enter S phase (reviewed in 6).  In 
addition to arresting cells in G1 phase, p53 negatively regulates almost all cell cycle phases 
by inhibiting cyclin A and cyclin B. p53-mediated cell cycle arrest is considered as an 
intracellular protective machinery against oncogene activation and DNA damage which leads 
to mutations, chromosomal aberrations and carcinogenesis (reviewed in 65). 
 
Table 1. Alterations of Rb in human tumors from the book Biology of Cancer by Robert Weinberg. 
 APOPTOSIS    
In response to severe stress signals, intracellular or extracellular apoptosis pathways will be 
activated to eliminate damaged cells. However, cancer cells evolved to acquire the ability to 
evade apoptosis by expressing anti-apoptotic proteins such as Bcl-2, along with its  family 
members (Bcl-xL, Bcl-w, Mcl-1, A1) which suppress two pro-apoptotic proteins Bax and 
Bak, as well as sequestering BH3-only proteins such as Puma and Noxa (reviewed in 66). As 
the guardian of genome, p53 can transcriptionally activate Bax and BH3-only proteins Puma 
and Noxa, which liberate Bax and Bak from the binding of anti-apoptotic proteins to release 
cytochrome C from the outer membrane of mitochondria to activate caspase 9-mediated 
apoptosis signaling (reviewed in 6). Mitochondrial p53 directly activate the oligomerization 
of Bax and Bak to promote apoptosis (reviewed in 67). Many studies have shown that 
chemotherapy- or radiation-induced tumor regression is p53-dependent, which highlights its 
role as a key pro-apoptotic factor (reviewed in 68,69).    
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 ANGIOGENESIS     
Unlike normal tissues, angiogenesis in tumor tissues is continuous instead of transient. Since 
the sustained proliferation of cancer cells requires relatively more nutrients, cancer cells need 
more vessels to support their growth. The angiogenetic signaling is regulated by several 
factors, for instance, VEGF-A can bind to VEGFR, receptor in vascular endothelial cells. 
The VEGF gene can be upregulated by HIF1-α and other oncogenes (reviewed in 70). It has 
been shown that p53 inhibits angiogenesis by targeting HIF1-α to degradation through 
physical binding 71. p53 can also transcriptionally repress a group of pro-angiogenic genes 
including VEGF, COX-2 and upregulate anti-angiogenic genes including Thrombospondin-
1, Brain-specific angiogenesis inhibitor 1, Ephrin receptor A2 and angiogenetic collagens 
(reviewed in 72). Importantly, wild type p53 status is required for the success of anti-
angiogenic therapy in mouse experiments 73,74. The mechanism is elusive, but it implies the 
central role of p53 in regulating signaling pathways across different types of cells in the 
microenvironment. 
 METASTASIS     
During cancer progression, cancer cells can invade neighboring tissues by breaking down 
extracellular matrix (ECM) and cell-to-cell adherence and metastasize to distant organs 
through EMT process. Metastasis is considered as the major cause of cancer-related death 
(reviewed in 75). It has been shown that mutant p53 can promote metastasis by its gain-of-
function, while wild type p53 could prevent metastasis. Indeed, in hepatocellular carcinoma, 
by activating its target gene MDM2, p53 can cause degradation of Snail, a key repressor of 
E-Cadherin and inducer of N-Cadherin 76. TGF-β is the key regulator for EMT process, it has 
been summarized that TGF-β can activate RTK signaling, cytokine signaling, β-catenin 
signaling, Notch signaling and Sonic Hedgehog signaling. Many of these pathways can in 
turn induce the expression of ligands that comprise TGF-β family (reviewed in77). It is also 
proven that wild type p53 inhibits EMT process that is induced by TGF-β 33. TGF-β is shown 
to activate Smad3/4 signaling and downregulate total endogenous p53 levels by 
transcriptionally upregulating MDM2 78. Interestingly, it has been found that MDM2 can also 
promote metastasis by degrading E-Cadherin independent of p53 79. It is possible that p53 
can inhibit metastasis independent of MDM2. For example, p53 can inhibit the expression of 
ZEB1 by transactivating miR200 33. It is known that HIF1-α is also involved in metastasis by 
activating EMT regulators and p53 can directly bind and inhibit HIF1- α, which highlights 
its role as anti-metastasis factor (reviewed in 72). 
 REPLICATIVE IMMORTALITY    
In order to acquire unlimited replication, cancer cells need to pass through two transition 
barriers called senescence and apoptosis, also known as crisis. It was found that human cancer 
cells have high expression of telomerase which maintains length of telomeres, that is required 
for cell immortalization and prevention of DNA end-to-end fusion (reviewed in 80). In 
mammalian cells, telomere shortening results in p53 activation leading to senescence to 
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prevent tumor growth 81. In addition, it was found that p53 can suppress telomerase activity 
separated from its cell cycle checkpoint function and loss of p53 function is often correlated 
with high expression of telomerase in different types of human cancers 82. 
 REPROGRAMING ENERGY METABOLISM    
Cancer cells prefer to utilize glycolysis to produce energy even under aerobic conditions. 
Tumor-associated mutant p53 has been proven to stimulate Warburg effect by enhancing 
GLUT1 translocation to the plasma membrane 83. It has been shown the mutant p53 can 
cooperate with HIF-1 to transcriptionally activate ECM components and promote tumor 
progression 84. Since the ATP production efficiency of glycolysis is around 18-fold lower 
than oxidative phosphorylation, cancer cells need more glucose than normal cells. This 
characteristic is utilized by PET-CT to detect glucose isotope to visualize tumors in clinic 85. 
It is known that HIF1-α is the key factor in reprogramming energy metabolism in tumors. 
HIF1-α can activate glycolysis and repress TCA cycle by inducing PDK1 86. Hypoxia can 
increase the level of p53 and therefore select for cells with mutant p53 71. It has been shown 
that p53 can inhibit glycolysis not only by directly degrading HIF-1α 71 but also by activating 
TIGAR that degrades fructose-2,6-bisphosphate thus blocking glycolysis 87. In addition, p53 
enhances oxidative phosphorylation by activating SCO2 which is essential for the COX2 
biogenesis and maintains aerobic ATP production 88.  
 IMMUNE SURVEILLANCE   
Recently, it has been reported that p53 signaling can be activated by interferon signaling. In 
turn, p53 could directly activate expression of immune-response genes including CC-
chemokine ligand 2, IFN regulatory factor 5, IRF9, protein-kinase RNA-activated, toll-like 
receptor 3 and many others (reviewed in 89). Moreover, mutant p53 expression is correlated 
with high expression of PD-L1 which binds to its receptor PD-1 on T cells, thus inhibiting T 
cell receptor (TCR) signaling and T cell proliferation 90,91. It has been discovered that wild 
type p53 can downregulate the expression of PD-L1 through miR-34 which binds to 3’ UTR 
of PD-L1 91. Interestingly, restoration of wild type p53 by small molecules can activate both 
innate and adaptive immunity and enhance immune response in combination with anti-
CTLA-4 or anti-PD1/PDL-1 therapy 92. 
 GENOME STABILITY    
p53 is also known as the guardian of genome. It maintains genome stability through  
regulation of DNA repair, or elimination of cells with damaged DNA via apoptosis, cell cycle 
arrest and senescence. Inactivation of p53 either through MDM2-mediated degradation or 
hot spot mutation leads to genome instability (reviewed in 93–95).  In addition, MDM2 could 
promote genome instability independently of p53 96,97. Recently it has been found that p53 
cooperates with PCNA to ensure proper progression of DNA replication 98,99. p53 is essential 
to prevent transcription-replication collision and topological stress, which further supports 
its role in maintaining genome stability 100.  
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Figure 3. Schematic view of p53 and cancer hallmarks. While cancer acquired the ability to promote angiogenesis, 
proliferation, metastasis, immortalization and energy reprogramming, cancer can also escape immune surveillance, 
growth repression and apoptosis. p53 is found to repress all these cancer hallmarks directly or indirectly inhibiting 
genes that are critical for each process.  
3 PHARMACOLOGICAL TARGETING OF P53   
 SMALL MOLECULES TARGETING MDM2/MDMX   
Currently, a number of compounds have been invented to reactivate wild type p53 by targeting 
the major p53 negative regulators, MDM2 and MDMX. MDMX does not degrade p53 directly 
but enhances MDM2’s activity via physical binding ( reviewed in 101). The crystal structure of 
MDM2 in complex with p53 peptide indicates three amino acid residues of p53: Phe19, Trp23 
and Leu26, that are essential for MDM2 binding. Most of the MDM2 inhibitors are designed 
to prevent the interaction between MDM2 and p53 by mimicking these residues of p53 ( 
reviewed in 102 , see Table 2 for some examples). Nutlin-3 is the first small molecule  discovered 
to disrupt p53-MDM2 interaction. It has been reported that nutlin-3 can induce p53-dependent 
apoptosis or cell cycle arrest in cancer cells 103,104.  
Induction of apoptosis or senescence by p53 depends on the balance of pro- and anti-apoptotic 
factors. Apoptosis is regulated by pro-apoptotic proteins Puma, Noxa and anti-apoptotic 
proteins such as Bcl-xL, Bcl-2, Mcl-1. When pro-apoptotic proteins gain the ground, the 
activation of p53 tends to lead to apoptotic effect. Some studies suggest that Nultin-3 can 
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induce cell death independent of p53 transcriptional activity. They found that Nutlin-3 induces 
a direct translocation of p53 protein from nucleus to mitochondria, where p53 can directly 
activate pro-apoptotic Bcl-2 family members and induce apoptosis 105. Currently, several 
advanced Nultin-3-like MDM2 inhibitors are in Phase 1 or 2 clinical trials,  including RG7112, 
MI-773 and DS-3032b. Noteworthy, cell-penetrating stapled peptides that inhibit both MDM2 
and MDMX have been developed recently, which are highly effective, able to enter every cell 
in a variety of cell lines and activate p53. In comparison to Nutlin-3, these stapled peptides are 
more stable, more permeable, more specific and have higher affinity 106. In addition, a more 
efficacious MDM2 inhibitor has been developed based on the proteolysis targeting chimera 
(PROTAC) concept which is called PROTAC MDM2 degrader. This molecule consists of a 
ligand to MDM2 inhibitor (Nutlin-3), a ligand to the E3 ubiquitin ligase and a linker connecting 
the two ligands. This molecule not only stabilizes p53 but also targets MDM2 to degradation 
and effectively induce tumor regression in vitro and in vivo experiments, providing a new 
therapeutic strategy for the treatment of human cancers 107,108.  Other compounds such as 
HLI98, MEL23/24 designed to inhibit the E3 ubiquitin ligase activity of MDM2 have been 
shown to induce p53-dependent transcription and apoptosis, while other p53-independent 
effects were also observed 109,110.    
 SMALL MOLECULES REACTIVATING MUTANT P53      
There are also compounds which target mutant p53 and restore p53 activity. PRIMA-1MET (also 
known as APR-246) which has successfully completed a Phase 1 clinical trial and is currently 
being tested in Phase II and III trials in combination of carboplatin in ovarian cancer patients 
(NCT02098343), in combination with 5-azacitidine in myeloid malignancies, myelodysplastic 
syndrome and chronic/acute myeloid leukemia (NCT04214860, NCT03745716, 
NCT03588078, NCT03072043). PRIMA-1MET induces formation of covalent adducts in 
mutant p53R175H and p53R273H proteins and restore wild type p53 activity 111. However, the exact 
mechanism has not been fully elaborated yet. PRIMA-1MET can also reactivate p53 homologues 
such as TAp73a, TAp73b and TAp63g8 112.  
Compounds such as PK083, PK5174, PK5196, PK7088 and various benzothiazoles seem to be 
able to restore p53 activity in cell lines harboring the Y220C mutation, a hotspot mutation 
which has been found in nearly 75,000 new cancer cases per year (reviewed in 102). Current 
compounds that reactivate wild type and mutant p53 and their application status are listed in 
Table 2 and shown in Figure 4.  
With the development of cell-based screening, more and more p53 activators have been found 
but their mechanisms of action are not fully understood. RITA was reported to target wild type 
and mutant p53 and induce apoptosis in cancer cells without killing normal cells, which makes 
it a promising compound for cancer treatment 113. However, accumulating data showed that 
RITA has other targets in addition to p53; it also induces apoptosis in a p53-independent way 
114. In order to stratify cancer patients, the mechanism of all the compounds which reactivate 
p53 should be evaluated carefully in pre-clinical models.   
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Table 2. Examples of compounds targeting MDM2 or mutant p53 and their status in clinical trials. 
 SMALL MOLECULES INHIBITING P53 
Although it is generally accepted that reactivation of p53 is a promising strategy to treat cancer, 
it also has dark sides. p53 is a key pro-apoptotic factor and it has been reported that the side 
effects of cancer therapy are related to p53-mediated growth arrest or apoptosis in normal 
tissues in mice such as spleen, thymus, lymphoid, hematopoietic organs, intestine epithelium. 
These tissues are drug- and irradiation-sensitive due to p53 activation. Consistently, p53-
deficient mice survive high dose of irradiation that is lethal to p53 wild type mice 115. Moreover, 
it is believed that p53 could serve as a resistance factor in cancer cells which undergo cell cycle 
arrest or senescence and therefore might be protected from chemo- and irradiation- induced 
apoptosis (reviewed in 116).  
Hence, it seems  reasonable to inhibit p53 to avoid cancer treatment side effects in normal 
tissues or enhance chemo- and irradiation sensitivity in certain types of cancers under certain 
conditions. In 1999, PFT-α was screened as a specific p53 inhibitor by using LacZ-encoding 
β-Gal p53-dependent reporter system 115. Afterward, PFT-α has been shown to protect mouse 
neurons against death and enhance the recovery of subventricular zone of mice after brain 
stroke 117. What’s more, PFT-α inhibits doxorubicin-induced cardiac cell apoptosis in mouse 
hearts and is protective from cisplatin-induced hair loss and toxic effects in multiple organs in 
mice. Interestingly, in cells lacking apoptotic signaling, inhibition of p53 by PFT-α can alter 
cell status from cell cycle arrest to mitosis, which could sensitize these cells to chemo- and 
irradiation therapy (reviewed in 116).  
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However, inhibition of p53 could result in survival of genetically altered cells which are 
tumorigenic in a long term. Although it was demonstrated that transient inhibition of p53 is not 
associated with cancer initiation in mouse models and is less dangerous than p53 deficiency, 
some experiments indicated that cells treated by chemotherapeutic drugs followed by PFT-α 
display a high rate of genome abnormality which can contribute to carcinogenesis in a long 
term (reviewed in 116). Thus, the idea of whether PFT-α could be used to protect cancer patients 
from cancer therapy side effects is still controversial. More tests in different models need to be 
done pre-clinically.  
In 2006, another small molecule called PFT-μ was isolated by Strom E. et al. to inhibit p53. To 
be specific, they found that PFT-μ can prevent p53 from binding to anti-apoptotic proteins 
Bcl-xL and Bcl-2, therefore protect primary mouse thymocytes from p53-induced apoptosis 
118, and protect mice from lethal hematopoietic syndrome upon radiation. It was confirmed 
that PFT-μ can protect p53 wild type cancer cell lines RKO and ML-1 from Nutlin-3-induced 
apoptosis, indicating that PFT-μ is a specific inhibitor of mitochondrial p53 without affecting 
p53 transcriptional activity 105. 
 CHALLENGES IN TARGETING P53 
One challenge for the application of MDM2 inhibitors is that the inhibition of MDM2 or 
MDMX by itself could also affect cellular activity, since more and more evidence indicate that 
MDM2 and MDMX are involved in regulation of gene expression, DNA repair, chromatin 
modification and mitochondrial dynamics independent of p53 (reviewed in 119).  
Although MDM2 is well-known proto-oncogene and could serve as a bio-marker and 
therapeutic target for cancer patients, potential side effects due to MDM2 inhibition because of 
the p53 activation in normal cells, especially long-term inhibition, should also be taken into 
consideration. MDM2 is also involved in other potent biological processes including metabolic 
activity, pro-inflammation and immune response (reviewed in 120). Therefore, more studies 
focused on long term side effects of MDM2 inhibitors should be done in mice. Relevant 
information could also be obtained from clinical trials of MDM2 inhibitors.  
Worth to note, it was found that MDM2 can degrade not only wild type but also mutant p53, 
which brings up another challenge. One study showed that MDM2 can degrade p53175H and 
p53241F (reviewed in 121). Therefore, the application of MDM2 inhibitor, for example Nutlin-3 
in cancer cells harboring mutant p53 will possibly have opposite outcome. Inhibition of MDM2 
could result in accumulation of mutant p53. Once stabilized, with its gain-of-function, mutant 
p53 promotes tumorigenesis, genome instability, resistance to chemotherapy and metastasis. 
In mouse models, mutant p53 correlates with more invasiveness and metastasis compared to 
the absence of p53 (reviewed in 122).  
While conventional chemotherapy and irradiation can stabilize wild type p53, it could also 
stabilize mutant p53. It has been shown in lung tumor that mutant p53  can accumulate in 
response to irradiation, which is unwanted effect of cancer therapy. It has been also 
13 
 
demonstrated in DLD-1 cells, that topoisomerase inhibitor CPT can degrade MDM2 but 
increase mutant p53 123,124. Therefore, the identification of p53 status whether it is wild type or 
mutant is critical for therapy determination. However, it is practically difficult because 
immunohistochemistry cannot distinguish between wild type and mutant p53, unless there is a 
very high level of p53, indicating p53 mutation 125. The detection of mutant p53 has been 
improved with the advancement of DNA and cDNA sequencing, which could be used for the 
identification of p53 mutations in clinic 126. In some cancer cells, mutant p53 level is low but 
could be increased and promote tumorigenesis when MDM2 is inhibited. Therefore, mouse 
models with different types and status of p53 should be tested with MDM2 inhibitors, 
chemotherapies and irradiation to evaluate their anti-cancer and side effects.     
 
Figure 4. Summary of current small molecules targeting MDM2/MDMX to reactivate p53 by different strategies, 
including disrupting MDM2/p53 complex, inhibiting MDM2 E3 ligase activity, inducing MDM2/MDMX 
degradation; besides directly binding and reactivating p53, RITA also stabilizes p53 by inhibiting HPV E6 which 
degrades p53. Reactivated p53 induces cell cycle arrest or apoptosis by transcriptionally activating its target genes. 
Mitochondrial p53 also induces apoptosis by stabilizing Bax and Bak. Pifithrin-α is described to inhibit p53 
transcriptional activity while pifithrin- μ is described to inhibit mitochondrial p53. Both have been shown to 
prevent p53 activity. 
4 NOVEL APPROACHES TO IDENTIFY TARGETS AND 
MECHANISMS OF ACTION OF SMALL MOLECULES  
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 TARGET IDENTIFICATION 
From the clinical point of view, it is imperative to know the targets of drugs for better efficacy 
of treatment. Although a drug is originally designed to target one factor that is the major cause 
of a certain disease, it could have multiple targets and we should consider cell as a complexity 
instead of looking at a single target in vitro. Target identification techniques, whether it is 
machine learning algorithms or biological experiments, are usually based on principles of 
biophysics, biochemistry, genetics, chemical biology and others. 
 NOVEL APPROACHES 
Biochemical methods are based on changes upon drug-protein physical interactions. In the last 
few years, a method called drug affinity responsive target stability (DARTS) has been 
developed, based on the principle that the protease resistance of the protein will be increased 
when it is bound by small molecules. This strategy is dependent on drug-protein interaction 
without requirement of drug modifications, which are needed, for example, for small molecule 
affinity chromatography. In addition, since DARTS does not require a washing step, it can be 
used to identify lower affinity binding of protein-drug interaction 127.  
Another approach called chromatographic co-elution (TICC) to detect drug targets under 
physiological conditions in vitro is based on liquid chromatographic shift after drug-protein 
interaction. Other approaches such as metabolic labeling called stable-isotope labeling by 
amino acids in cell cultures (SILAC) and chemical labeling called isotope-coded affinity tag 
(ICAT) are also used in many studies.  
Genetic method by using RNAi or CRISPR Cas9 KO technique can also be used to identify 
drug targets. For example: positive-selection screen based on cell viability can be used to 
confer drug resistance to identify drug targets; negative-selection screen is also based on cell 
viability, however, it is usually used to identify genes that can sensitize to a drug and the 
signal is low compared to positive-selection screen (reviewed in 128). If the silencing of a 
gene has similar biological effect to a compound, it is suggesting that the protein is inhibited 
by this compound.  
We can also use computational analysis to identify targets of new drugs by comparing them 
to documented profile of other compounds such as gene expression or growth suppression in 
different cancer cell lines (reviewed in 129). It is recommended to combine several approaches 
to fully characterize any on-targets and off-targets effects to better understand the action of 
small molecules. 
 CELLULAR THERMAL SHIFT ASSAY AND THERMAL PROTEOME 
PROFILING  
Another approach, cellular thermal shift assay (CETSA), is used based on the phenomenon that 
protein thermal stability will be changed after protein-drug interaction. After heating cells with 
or without drug treatment at several increasing temperatures, cells are lysed, then soluble and 
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precipitated proteins are separated by centrifugation. The soluble proteins will be detected by 
WB, while unfolded proteins precipitate. This allows to determine if the thermal stability of 
those potential target proteins is changed, thus suggesting target-drug interaction 130. While 
DARTS is used to enrich target proteins that are resistant to protease and non-target proteins 
are digested after protease treatment, CESTA is used to identify drug-protein engagement 
indicated by ΔTm (melting temperature shift) (Figure 5). Since DARTS and CETSA are based 
on antibody readout, they are limited to a small number of proteins.  
Both DARTS and CETSA can be combined with Mass spectrometry for large scale drug targets 
detection. Thermal proteome profiling (TPP) (for the pipeline, see Figure 6) is a proteome-
wide CETSA with readout for around ~6000 to 10000 proteins. TPP has been used for unbiased 
identification of direct and indirect drug target proteins in several studies and has been 
optimized by combining several algorithms for analysis 131. Besides drug targets investigation, 
TPP can also be used to study mechanism of drug action and metabolic pathways since it allows 
to study PTMs, protein-protein interactions and protein function upon overexpressing or 
knocking out a gene. 
 
Figure 5. Melting curve from CETSA assay to study protein-drug interaction. Figure is from Sygnature Discovery: 
https://www.sygnaturediscovery.com/drug-discovery/bioscience/biophysical-assays/cellular-thermal-shift-assay-
cetsa/ 
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Figure 6. Pipeline of Thermal Proteome Profiling. (1) Cells are incubated with or without the compound of interest, 
then cell extracts will be obtained. Alternatively, compound can be added to the cell extracts. (2) Each sample will 
be divided into 10 aliquots. (3) Each aliquot will be heated at indicated temperature. (4) After digestion by trypsin, 
each sample will be labeled by different TMT10 isotope tag. (5) All samples will be mixed and analyzed by LC-
MS/MS, the intensity of each labeled ion will be used to fit the melting curve. (6) The melting curve Tm of each 
protein will be separated by two conditions. Mikhail M. Savitski et al. Science 2014;346:1255784. Copyright © 
2014, American Association for the Advancement of Science 
 TRANSLATOME ANALYSIS 
Although transcriptome analysis with tools such as RNA extraction followed by cDNA 
microarray or RNA sequencing provides good indications about gene expression upon drug 
treatment for identifying drug targets, there is still discrepancy between mRNA level and actual 
protein level because of on-going variations of protein synthesis and protein degradation. 
Therefore, translatome analysis which can reveal mRNAs that are recruited by ribosomes for 
protein synthesis provides additional and important information for cell function study. 
Translation comprises of three steps: initiation, elongation and termination. Briefly, during 
initiation, mRNA will be recruited by eIFs to the ribosome complex, which recruits tRNA that 
contains complementary three nucleotides to the codon of mRNA. Each tRNA will be bound 
to a specific peptide, which usually starts with methionine corresponding to start codon AUG 
in eukaryotes; during elongation, polypeptide will be formed as tRNA with its specific peptide 
is recruited to mRNA, which leads to the shift of ribosomes on mRNA; finally, once the 
translation reaches to stop codons on mRNA, the polypeptide chain will be released. Herein, I 
will briefly describe three translatome analysis methods that are being used in my study. 
Polysome profiling: Since the rate of initiation is a limiting factor of translation, a measurement 
of the association of cellular mRNA and ribosomes could reflect translation in general. First of 
all, cell extracts will be prepared in cycloheximide (CHX), used to inhibit translational 
elongation; translated mRNAs bound by polysomes will be separated by centrifugation through 
10% to 50% density of sucrose gradient; the fraction of polysome-free RNA, small and large 
ribosomal subunits will be separated by monitoring the absorbance at 254 nm (A254); isolated 
RNA from each fraction can be pooled for microarray or RNA-seq analysis. 
Ribosomal profiling: Instead of using centrifugation, cell extracts will be treated with RNase I 
to digest the regions on mRNA that are not bound by ribosomes, the remaining ribosomes will 
be selected by sucrose cushion with a fragment size of approximately 30 nucleotides, protected 
RNA will be further used for RNA-seq analysis. 
Ribosome-affinity purification: Genetically modified cells are first constructed to express 
affinity-tagged ribosomal proteins that are controlled by cell-specific promotor. After affinity 
selection, cells are collected and tagged ribosomal proteins are extracted for study. RNA 
isolated from captured ribosomal proteins can be measured by RNA-seq analysis. 
Translatome analysis can be used to study the response to various stress signals such as 
hypoxia, infection, nucleotide starvation, DNA damage, inflammation, apoptosis and 
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endoplasmic reticulum stress. Besides, this analysis can be applied to study drug action or 
comparison of normal cells and cancer cells. However, since these translatome analysis 
methods are focused on the initiation of translation, post-translational process such as protein 
degradation should also be taken into consideration. Translatome analysis in combination with 
mass spectrometry is better for understanding the entire picture of cell function (reviewed in 
132). 
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5 AIMS OF THE THESIS 
A number of compounds have been developed to reactivate p53 and some of them are already 
in clinical trials. The thesis aims to address p53-dependent and -independent functions of 
small molecules that target p53. 
Specific aims: 
1. To understand p53-independent anti-cancer mechanism of RITA along with other two 
intriguing compounds, aminoflavone and oncrasin-1 (Paper I) 
2. To investigate the action of p53 inhibitor pifithrin-α on p53 as well as its function 
independent of p53 (Paper II) 
3. To investigate the effect of RITA on mRNA translation (Paper III) 
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6 RESULTS AND DISCUSSION 
The thesis is focusing on the studies of the p53-dependent and -independent mechanisms of 
p53 reactivating compounds  and p53 inhibitor. 
Paper I 
Thermal proteome profiling identifies oxidative-dependent inhibition of major oncogenes 
transcription as new therapeutic mechanism for selective anticancer compounds 
Sylvain Peuget, Jiawei Zhu, Gema Sanz Santos, Madhurendra Singh, Massimiliano Gaetani, 
Xinsong Chen, Yao Shi, Amir Ata Saei, Torkild Visnes, Mikael Lindström, Ali Rihani, Lidia 
Moyano-Galceran, Joseph Carlson, Elisabet Hjerpe, Ulrika Joneborg, Kaisa Lehti, Johan 
Hartman, Thomas Helleday, Roman Zubarev, and Galina Selivanova.  
 
Analysis of the GI50 data of several thousand of compounds in NCI 60 cell lines allowed to 
identify  sensitivity correlation profiles of Aminoflavone and Oncrasin-1 that are similar to 
RITA. Based on the analysis, we confirmed that these three compounds share a similar anti-
cancer activity in a set of cancer cell lines. We found that the three compounds can efficiently 
kill MCF7, MCF7p53KO, U2OS, OVCAR3 and T47D cancer cell lines in a p53-independent 
but ROS-dependent manner, as co-treatment of antioxidants such as resveratrol and NDGA 
rescued their killing effect in either p53KO cells or p53 mutant cells. Our q-PCR and Western 
blot (WB) results both showed that pro-apoptotic genes such as Puma, Noxa are greatly 
activated while pro-survival genes, also known as oncogenes, such as MDM2, MDMX, Mcl- 
1, PPM1D, are inhibited by these three compounds. We confirmed that this phenomenon is 
also mediated by ROS induction and is independent of p53. WB results also showed that DNA 
damage and apoptotic signatures, such as γH2AX and PARP cleavage, are induced by these 
three compounds in a ROS-dependent manner and p53- independent manner. In addition, 8-
oxoguanine is induced by three compounds, indicating oxidative DNA damage, as shown by 
immunofluorescence. 
To investigate what is the common pathway that is affected by these compounds, first we 
performed Thermal proteome profiling (TPP) to identify what are the common targets of these 
three compounds. We identified 90 common targets between 2 compounds and 8 common 
targets among all three compounds. After clustering the pathways of these common targets by 
Gene Ontology analysis, we found RNA processing to be affected by all three compounds. To 
investigate the effect on RNA processing, we  determined the rate of EU incorporation by 
immunofluorescence and the level of RNA polymerases by WB. Not surprisingly, all three 
compounds efficiently inhibited transcription machinery of cancer cells. EU incorporation is 
inhibited and RNA polymerase II and its Ser2-phosphorylated form are inhibited due to 
proteasome degradation.  
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It was previously found that RITA can cause DNA replication stalling. Therefore, to understand 
if the transcription inhibition was due to DNA replication stalling, we performed cell 
synchronization experiment, using double thymidine block to arrest the cells in G1/S phase and 
lovastatin treatment to arrest the cells in G1 phase. We found that transcription is inhibited by 
three compounds in G1 phase, thus indicating that inhibition of transcription is causing DNA 
replication stalling, but not vice versa. Consistently, the compounds known to inhibit RNA Pol 
II-mediated transcription, such as CDK12/13 inhibitor THZ531 and  actinomycin D, also share 
microarray profiles similar to these three compounds, including oncogene repression. This we 
further confirmed by WB. We found that the global transcription inhibition by these 
compounds is through ROS induction as ROS inhibitor resveratrol partially rescued the 
inhibition of RNA polymerase II (Pol II) complex by three compounds, as detected by WB. 
Not only oncogenes were repressed, but also genes that are involved in homologous 
recombination (HR), such as RNF168, RNF8 and Rad51, are also downregulated by the three 
compounds. Our HR reporter assay confirmed the impairment of HR upon these treatments. It 
is known that cancer cell survival relies on major DNA repair pathways, such HR, non-
homologous end joining (NHEJ), single strand break repair (SSBR), and others. Breast and 
ovarian cancers with BRCA1/2 mutations, which confer a defect in HR, prefer SSBR regulated 
by ADP-ribose polymerase (PARP) to repair DNA. Several PARP inhibitors have been 
approved in clinic for the treatment of triple negative breast cancer patients with BRCA1/2 
mutations. Therefore, since our three compounds inhibit HR, we hypothesize that their 
combination with PARP1 inhibitors will have better anti-cancer effect. Indeed, we observed 
strong synergistic effect in our cancer lines as well as in primary ovarian and breast cancer 
patient samples. 
In conclusion, RITA, Aminoflavine and Oncrasin-1 increase intracellular ROS levels, leading 
to global transcription inhibition in a p53-independent manner. As the consequence of 
transcription inhibition, early expressed oncogenes are repressed, this leads to cell growth 
suppression. Further, genes that are involved in DNA repair, especially HR, are also inhibited, 
so that cancer cells become more vulnerable to treatment of PARP1 inhibitors (the model is 
presented in Figure 7). Our study also shows that TPP approach could be used to identify the 
mechanism of action of small molecules, which is important for drug development.    
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Figure 7. RITA, AF and Onc-1 inhibit transcription machinery, induce replication stress, and downregulate 
oncogenes through ROS accumulation, which leads to robust cancer cell death. Since RITA, AF and Onc-1 repress 
HR factors such as Rad51, RNF8, RNF168, addition of PARP inhibitors could lead to synergistic cell death effect 
in cancer cells with functional HR machinery.  
 
Paper II 
Pifithrin-α alters p53 post-translational modification pattern and differentially inhibits 
p53 target genes 
Jiawei Zhu, Madhurendra Singh, Galina Selivanova and Sylvain Peuget. 
To investigate PFT-α inhibition efficiency on p53, we treated MCF7 and A375 cells with 
Nutlin-3 to induce cell cycle arrest or apoptosis specifically through p53 activation. We found 
that PFT-α cannot prevent cancer cell growth suppression upon p53 activation. The same result 
was observed in immortalized fibroblasts. However, in primary fibroblasts, PFT-α by itself 
could enhance the growth which compensates for Nutlin-3-induced growth suppression. We 
also tested another p53 inhibitor PFT-μ, which can prevent the action of p53 in mitochondria, 
but no rescue of growth suppression was observed with PFT-μ in MCF7 and A375 cells as 
well. 
It was originally described that PFT-α can inhibit p53 transcription activity by preventing p53 
DNA binding ability. We selected a panel of p53 target genes and validated them by comparing 
MCF7 p53WT and MCF7 p53KO upon Nutlin-3 treatment. Our qPCR results showed that the 
addition of PFT-α, especially with 12h pre-treatment displays differential inhibition of p53 
target genes. To be specific, BBC3 (PUMA), PIG3, TP53INP1, RRM2B, PPM1D (WIP1), 
SESN1 and TIGAR induction upon Nutlin-3 was moderately inhibited (decreased by 35% to 
50%) by PFT-α, while the effect on the transcription of ZMAT3 and CDKN1A (p21) was limited 
(induction decreased by only 23% and 25%, respectively). Moreover, no significant 
transcriptional inhibition was observed for MDM2 and DRAM. We also confirmed by WB that 
MDM2 and p21 were not inhibited at protein level by PFT-α upon Nutlin-3-induced p53 
stabilization. 
To understand how PFT-α differentially inhibit p53 target genes, we performed WB to check 
the effects of PFT-α on total p53 level and phosphorylated Ser33 of p53 upon Nutlin-3 
treatment. We found total p53 protein level is not changed upon PFT-α, but we observed that 
phosphorylation of p53 on Ser33 upon Nutin-3 treatment was significantly inhibited by PFT-
α. Moreover, we treated MCF7 with doxorubicin to induce phosphorylation of p53 on residues 
Ser15 and Ser37 and PFT-α efficiently inhibited both Ser33 and Ser15 phosphorylation, but 
not Ser37 activated upon doxorubicin. We also observed robust inhibition of Ser33 and Ser15 
phosphorylation of p53 in A375 and HCT116 cell lines. It indicates that PFT-α can affect 
specific p53 PTMs, which could change the conformation of p53 resulting in different 
expression of its targets. To investigate the mechanism of how PFT-α alters PTMs of p53, we 
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hypothesized that PFT-α could decrease ROS to weaken phosphorylation of p53 because ROS 
is one of the main regulators of PTMs, especially phosphorylation. We performed DCFD-A 
staining and checked intracellular ROS level upon PFT-α with flow cytometry. In both MCF7 
and MCF7 p53KO cell lines, we found that PFT-α can decrease both basal ROS level and 
prevent ROS formation upon doxorubicin by activating AHR/NRF2 pathway independent of 
p53. PFT-α exerts antioxidant effect in mutant p53-expressing T47D and A375 p53KO cells 
with activation of NRF2 pathway but not in H1299 with low expression of AHR. We 
investigated whether PFT-α antioxidant activity leads to attenuation of p53 PTMs. In MCF7 
cells treated with Nutlin-3, addition of another antioxidant, NAC, had no effects on Ser33 
phosphorylation of p53, while PFT-α strongly inhibited it. Therefore, we could not link the 
antioxidant effect of PFT-α to its inhibition p53 PTMs. 
In conclusion, the efficiency of PFT-α as specific p53 inhibitor appears to be highly 
questionable and context-dependent. In our models, it did not inhibit p53-dependent cell cycle 
arrest and apoptosis and had a target gene- and model- dependent effect on p53 transcription, 
probably due to indirect inhibition of p53 PTMs, such as inhibition of kinases including 
DYRK2, CHK1, CHK2, CK2, HIPK2, JNK, LRRK2, p38, PKCδ, and PLK3 that 
phosphorylate p53. In addition, PFT-α has notable p53-independent effects, such as strong 
induction of the AHR pathway which results in decrease of ROS levels. AHR is a potent 
transcription factor that can regulate a series of signaling pathways. Therefore, it is possible 
that PFT-α can affect p53 activity by activating AHR. Moreover, its differential properties in 
normal primary cells and cancer cells may have interesting clinical potential in combination 
with p53-reactivating compounds. However, it has been shown that antioxidants can promote 
tumor growth and metastasis if the tumor is already formed. This is because cancer cells are 
under high metabolism and ROS stress, antioxidants can decrease the stress in cancer cells. 
Therefore, using PFT-α to treat cancer patient might lead to opposite effects. The effect of PFT-
α on cancer should be further evaluated in animal models. 
 
Paper III 
RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity 
Johannes Ristau, Vincent van Hoef, Sylvain Peuget, Jiawei Zhu, Bo-Jhih Guan, Shuo Liang, 
Maria Hatzoglou, Ivan Topisirovic, and Galina Selivanova & Ola Larsson. 
To investigate the effect of RITA on mRNA translation, we treated MCF7 cells with RITA for 
8h and performed polysome profiling to check the rate of engagement of mRNA and 
ribosomes. We found that RITA reduced actively translated mRNA (polysome fraction) with 
increase of 80S monosomes. Since we previously found that RITA efficiently kills cancer cells 
independent of p53, we speculated that RITA inhibits translation also regardless of p53. Indeed, 
polysome profiling analysis demonstrated that RITA inhibits mRNA translation in both MCF7 
and MCF7 p53KO cells. Consistently, incorporation of S-methionine and S-cysteine were 
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reduced upon RITA treatment. It was reported that RITA induce apoptosis through ROS 
accumulation. We wanted to know if RITA inhibits translation because of ROS induction, since 
it was found that ROS inhibits protein synthesis. Although we found that NAC completely 
rescued ROS induction upon RITA treatment, as shown by CellROX Deep Red dye staining, 
PARP cleavage and translation inhibition persisted in the presence of NAC.  
Next, we investigated if mTOR/4E-BP is mediating RITA-induced translation inhibition. 4E-
BP1 knock down by shRNA could not rescue RITA-induced translation inhibition assessed by 
polysome tracing. In addition, mTOR inhibitor Torin1 could not affect mTOR-mediated 
phosphorylation of downstream targets S6K and 4E-BP1. Thus, RITA inhibits translation 
independent of ROS and mTOR/4E-BP axis. 
Since phosphorylation of eIF2α decreases translation initiation, we checked if RITA inhibits 
translation through eIF2α phosphorylation. We found that RITA significantly induced eIF2α 
phosphorylation in MCF7, HCT116 and GP5d cells. Addition of integrated stress response 
inhibitor ISRIB partially rescued RITA-induced translation inhibition indicated by decrease of 
80S monosomes peak with polysome tracing assay, as well as increased incorporation of S-
methionine and S-cysteine. Because PERK can phosphorylate eIF2α, we wanted to investigate 
if RITA induces phosphorylation of eIF2α and translation inhibition through PERK activation. 
Indeed, PERK inhibitor GSK2606414 reduced eIF2α phosphorylation, translation inhibition, 
PARP cleavage and apoptosis upon RITA treatment. Moreover, we found that salubrinal, 
which inhibits eIF2α phosphatases and enhances eIF2α phosphorylation, enhanced apoptosis 
effect of RITA in both wild type and p53KO cells, while GSK2606414 had the opposite effect. 
Of note, we found that p53 activation and apoptosis effect upon RITA is also dependent on 
eIF2α phosphorylation by comparing HT1080 wild type and HT1080 KI with non-
phosphorylatable eIF2α mutant.  
We found that RITA strongly downregulates MDM2 and investigated the mechanism of how 
RITA inhibits MDM2 on its protein level. We hypothesized that the inhibition could be through 
proteasome, autophagy or microRNA-mediated translation inhibition. Therefore, we 
implemented proteasome inhibitor MG132, autophagy inhibitor chloroquine and DICER 
knock out (preventing microRNA-mediated inhibition of translation) to verify the mechanism. 
However, none of them rescued RITA-induced MDM2 inhibition (Figure 8). We addressed the 
question if the inhibition of MDM2 has impact on the effects of RITA. We manipulated MDM2 
level by overexpressing or knocking out with CRISPR-Cas9 to see if these can affect RITA-
induced apoptosis. We found that RITA can still efficiently downregulate survival genes and 
induce DNA damage signalling in both MDM2 overexpressing and knock out cell lines (Figure 
9), suggesting that MDM2 downregulation does not play a key role in this model. Although 
these data were not included in the final paper, they served for the development of the 
hypothesis and further supported the mechanism that this paper described. 
In conclusion, we found that the stress sensing eIF2α pathway is critical for RITA-induced 
mRNA translation inhibition and cell apoptosis. By using translatome analysis methods such 
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as polysome profiling, polysome tracing and S-methionine and S-cysteine incorporation, we 
could unravel the mechanism of action of small molecules, which is important for stratifying 
cancer patients.     
 
Figure 8. Investigation of the mechanism of MDM2 downregulation upon RITA. A) In MCF7 cells, MDM2 
protein level is still greatly inhibited by RITA in the presence of proteasome inhibitor MG132 which restored basal 
protein level of p53. B) In MCF7 cells, autophagy is inhibited by using Chloroquine, as judged by LC3II 
upregulation. MDM2 downregulation was not rescued by inhibition of autophagy and p53 level was not affected. 
C) MDM2, Mcl-1 are inhibited, DNA damage persists upon RITA treatment in HCT116 DicerKO cells, in which 
microRNA-mediated mRNA translation inhibition is attenuated. 
 
Figure 9. Investigation of the impact of MDM2 inhibition for RITA-induced cell killing effect. MDM2 is 
overexpressed in MCF7 cells, MDM2 KO is established in MCF7 p53KO cells to avoid p53-mediated cell death. 
Result demonstrates that RITA inhibits pro-survival genes such as p21, PPM1D and Mcl-1, and DNA damage 
persists upon RITA in either MDM2 overexpressing or MDM2 KO cell lines. 
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7 CONCLUDING REMARKS 
All three papers are focused on addressing the molecular mechanisms of small molecules. 
Originally, each of them was designed to target a specific protein. Nevertheless, it is also 
necessary to identify any other targets (since they will most likely be) and depict the action of 
a compound targeting several proteins instead of a one drug-protein connection. The small 
compounds studied in this thesis are all designed to target p53, the well-known tumor 
suppressor, which has been studied for four decades. However, there are still no p53 targeting 
drugs that have officially entered clinic to treat patients. Challenges remain for the development 
of p53 targeting drugs and one of them is the off-target effects of drugs, which is a big concern 
for researchers and clinicians. Thus, identification of drug targets appears to be important for 
providing more comprehensive information for drug application.  
In our first study, by performing high throughput approaches such as TPP assay, we managed 
to identify that transcription machinery is affected by RITA, Aminoflavone and Oncrasin-1 in 
a common p53-independent way, which has never been shown before in the study of these 
three drugs. TPP assay could provide hundreds of hits. Therefore, it is hard to identify what are 
the main targets of a compound. This is because TPP assay provides only physical compound-
protein/protein complexes interaction information instead of biological response information. 
It is practically difficult to verify each single target in biological models. Therefore, we used 
Gene Ontology analysis to cluster the common pathways that are affected by all three 
compounds and found most of the common hits that are involved in RNA processing. 
Biological experiments not only further confirmed our findings but also provided more detailed 
information. Inspired by our finding of global transcription inhibition by the compounds, we 
found that these three compounds can repress genes such as RNF8, RNF168 and Rad51 which 
are key HR factors. It is generally accepted that combination treatments are less toxic and are 
often more effective than monotherapy. Therefore, we combined PARP inhibitors which 
inhibit SSBR with RITA, Aminoflavone and Oncrasin-1 in vivo and ex vivo and observed 
strong synergistic effect. Thus, our study shows that TPP assay followed by Gene Ontology 
analysis is a powerful tool to investigate the molecular mechanism of drug action. In addition, 
it is easier to find the main targets studying in parallel several drugs displaying similar 
biological effects.  
While the first study is focused on the effect of transcription machinery, our next study 
addresses the action of mechanism of RITA at translational level. We performed translatome 
analysis using polysome profiling which provides information regarding the rate of mRNA 
translation by checking mRNA ribosome engagement. We found that RITA induces dramatic 
translation inhibition through phosphorylation of eIF2α in a p53-independent way. These two 
studies helped us to have a more comprehensive view on RITA action since we looked into 
both transcription and translation which are the basic mechanisms providing factors that 
regulate various cellular processes. In a future, it would be interesting to test whether the effect 
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of RITA on these two basic cellular processes are interdependent and whether the same or 
different targets are involved.  
 In the third study, we sought to understand how PFT-α inhibits p53 action and investigate any 
other targets except p53. We found that PFT-α can significantly inhibit phosphorylation of p53 
on Ser33 and Ser15 which is induced by Nutlin-3 or doxorubicin treatment. Correspondingly, 
PFT-α also alters p53 transcription activity as indicated by differential inhibition of p53 target 
genes upon Nutlin-3 treatment. Nevertheless, we do not have straightforward evidence to prove 
that inhibition of p53 PTMs leads to the differential inhibition of p53 targets in our model. To 
provide evidence for this, we need to introduce mutation in p53 on either Ser33 or Ser15 or 
both and test p53’s transcriptional activity. We found that PFT-α activates AHR/NRF2 
pathway to exert antioxidant effect. However, its antioxidant effect is not the cause of inhibition 
of p53 phosphorylation. Surprisingly, PFT-α fails to rescue p53 activation-induced cell growth 
suppression in cancer cell lines and immortalized fibroblasts. Notably, it induces primary 
fibroblasts cell growth and rescue Nutlin-3-induced growth suppression. We think that this is 
related to its antioxidant effect, as NAC also induces cell growth in primary fibroblasts. 
Therefore, due to the differential effects of PFT-α on normal versus cancer cells, we think it 
might be a good strategy to combine PFT-α and p53 reactivating compounds to treat cancer to 
protect normal tissues from side effects of therapy as it has been suggested in previous studies 
which showed significant protective effect of PFT-α in normal mouse tissues upon chemo and 
irradiation therapy. We can foresee that the inhibition of p53 is a controversial idea, because 
PFT-α might be an effective p53 inhibitor in some tissues and inhibition of wild type p53 might 
lead to genome instability and carcinogenesis. In addition, it has been shown that antioxidants 
can promote cancer metastasis. Future studies are needed to investigate the above mentioned 
aspects and to establish whether the strategy of p53 inhibition could be applied in clinic. 
We believe that our study provided an important message to researchers who work with p53 
and use PFT-α to investigate p53-mediated cellular processes, that PFT-α is not a pan-p53 
inhibitor as it is described. In the future it would be very interesting to find out which are the 
targets of PFT-α, using high-throughput approaches such as CRISPR-Cas9 screens or those 
described in this thesis.      
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